1800-272-662
Shopping Cart 0
countryflagAU
Login

USANA Health Sciences Inc

Consumer Defensive US USNA

17.83USD
0.18(1.02%)

Last update at 2026-03-10T20:00:00Z

Day Range

17.4318.02
LowHigh

52 Week Range

44.0169.60
LowHigh

Fundamentals

  • Previous Close 17.65
  • Market Cap1011.20M
  • Volume191764
  • P/E Ratio17.11
  • Dividend Yield3.03%
  • EBITDA104.48M
  • Revenue TTM927.89M
  • Revenue Per Share TTM48.15
  • Gross Profit TTM 804.71M
  • Diluted EPS TTM3.09

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 108.62M 170.64M 177.95M 150.50M 191.51M
Minority interest - - - - -
Net income 69.35M 116.50M 124.66M 100.53M 126.22M
Selling general administrative 262.30M 279.11M 261.19M 267.73M 275.06M
Selling and marketing expenses 434.79M 519.27M 487.86M 459.48M 525.13M
Gross profit 804.71M 968.57M 925.53M 873.40M 988.54M
Reconciled depreciation 21.41M 22.19M 22.51M 23.01M 16.84M
Ebit 86.20M 148.00M 153.98M 123.18M 171.51M
Ebitda 107.61M 170.19M 176.49M 146.19M 188.35M
Depreciation and amortization 21.41M 22.19M 22.51M 23.01M 16.84M
Non operating income net other - 0.51M 1.96M 4.37M 3.19M
Operating income 107.61M 170.19M 176.49M 146.19M 188.35M
Other operating expenses 890.99M 1016.27M 958.15M 914.71M 1000.89M
Interest expense 0.19M 0.06M 0.51M 0.07M 0.04M
Tax provision 39.27M 54.14M 53.28M 49.97M 65.29M
Interest income 3.79M 2.52M 2.54M 4.71M 4.43M
Net interest income 3.60M 2.46M 2.03M 4.64M 4.39M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 39.27M 54.14M 53.28M 49.97M 65.29M
Total revenue 998.60M 1186.46M 1134.64M 1060.90M 1189.25M
Total operating expenses 697.10M 798.37M 749.04M 727.21M 800.18M
Cost of revenue 193.89M 217.90M 209.11M 187.50M 200.71M
Total other income expense net 1.01M 0.45M 1.46M 4.31M 3.16M
Discontinued operations - - - - -
Net income from continuing ops 69.35M 116.50M 124.66M 100.53M 126.22M
Net income applicable to common shares 69.35M 116.50M 124.66M 100.53M 126.22M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 596.55M 577.74M 640.89M 516.93M 554.46M
Intangible assets 32.43M 30.44M 30.80M 29.84M 31.81M
Earning assets - - - - -
Other current assets 28.87M 26.97M 23.14M 25.54M 32.52M
Total liab 162.08M 182.62M 199.24M 165.22M 163.32M
Total stockholder equity 434.47M 395.12M 441.65M 351.71M 391.15M
Deferred long term liab - 7.50M 12.01M 10.28M 13.37M
Other current liab 105.02M 120.57M 125.31M 101.40M 102.92M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings 391.64M 344.64M 382.79M 306.15M 329.50M
Other liab 10.56M 21.83M 12.01M 11.85M 14.63M
Good will 17.37M 17.67M 17.37M 16.64M 16.82M
Other assets 50.68M 62.73M 66.99M 26.17M 23.92M
Cash 288.42M 239.83M 311.92M 234.83M 214.33M
Cash and equivalents - - - - -
Total current liabilities 143.83M 160.79M 168.07M 136.10M 148.69M
Current deferred revenue 20.88M 19.64M 15.95M 13.85M 15.05M
Net debt -281.52800M -232.75200M -303.30100M -226.50700M -214.32600M
Short term debt 6.89M 7.08M 8.62M 8.32M 20.77M
Short long term debt - - - - -
Short long term debt total 6.89M 7.08M 8.62M 8.32M -
Other stockholder equity 55.60M 50.01M 62.46M 59.45M 72.01M
Property plant equipment 111.69M 101.78M 100.44M 95.23M 92.03M
Total current assets 384.38M 365.12M 425.29M 329.28M 392.33M
Long term investments - - - - -
Net tangible assets 384.67M 347.01M 441.65M 305.24M 342.52M
Short term investments - - - 0.00000M 63.54M
Net receivables 7.21M 7.16M 7.42M 8.76M 14.03M
Long term debt - - - - -
Inventory 67.09M 98.32M 90.22M 68.91M 81.95M
Accounts payable 11.05M 13.51M 18.20M 12.53M 9.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -12.78700M 0.46M -3.62500M -13.90100M -10.38700M
Additional paid in capital - - - - -
Common stock total equity - 0.02M 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - 344.64M 382.79M 306.15M 329.50M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 54.80M 57.89M 62.35M 42.86M 18.13M
Deferred long term asset charges - - - - 3.35M
Non current assets total 212.17M 212.62M 215.60M 187.66M 162.13M
Capital lease obligations 6.89M 7.08M 8.62M 8.32M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -12.37000M -1.43900M -18.87300M 64.05M -57.95100M
Change to liabilities -2.65600M -16.02800M 22.53M -28.96900M 16.98M
Total cashflows from investing activities -12.37000M -14.18700M -33.96100M 47.49M -69.00300M
Net borrowings - - -0.04600M -0.06500M -
Total cash from financing activities -30.08800M -181.41200M -59.44200M -152.05200M -105.27700M
Change to operating activities -12.37000M -13.78700M 11.26M -23.61500M 17.07M
Net income 69.35M 116.50M 124.66M 100.53M 126.22M
Change in cash 47.67M -72.28400M 78.25M 20.45M -33.30100M
Begin period cash flow 243.65M 315.94M 237.69M 217.23M 250.53M
End period cash flow 291.32M 243.65M 315.94M 237.69M 217.23M
Total cash from operating activities 103.90M 121.23M 160.40M 126.73M 152.12M
Issuance of capital stock - - - - -
Depreciation 21.41M 22.19M 22.51M 23.01M 16.84M
Other cashflows from investing activities 4.55M 0.01M 0.00600M 0.02M 0.38M
Dividends paid - - - - -
Change to inventory 21.88M -10.50100M -16.78400M 12.99M -23.10100M
Change to account receivables - - 0.28M 0.23M -0.65800M
Sale purchase of stock -25.38200M -177.83700M -57.02900M -150.00000M -105.37500M
Other cashflows from financing activities 6.29M -3.57500M 57.59M 2.95M 0.10M
Change to netincome 6.29M 11.39M 12.67M 11.99M 17.46M
Capital expenditures 10.40M 12.76M 15.09M 16.57M 11.43M
Change receivables - - - - -
Cash flows other operating - 6.83M 3.57M 15.45M -2.28400M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -74.37200M 67.00M 22.18M -22.16100M
Change in working capital 6.85M -28.86000M 0.56M -8.79000M -7.74900M
Stock based compensation 13.33M 14.30M 14.39M 15.54M 14.96M
Other non cash items 0.14M 0.06M 0.70M 0.08M 1.15M
Free cash flow 93.50M 108.46M 145.31M 110.16M 140.69M

Peer Comparison

Sector: Consumer Defensive Industry: Packaged Foods

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
USNA
USANA Health Sciences Inc		 0.18 1.02% 17.83 17.11 16.89 1.07 2.11 0.76 5.94
NSRGF
Nestle SA		 -0.88 0.85% 102.12 26.86 18.76 3.13 7.10 3.81 21.70
NSRGY
Nestle SA ADR		 -1.86 1.79% 101.81 26.82 18.66 3.18 7.07 3.81 21.70
KHC
Kraft Heinz Co		 -0.78 3.19% 23.66 15.59 11.79 1.64 0.88 2.34 11.32
DANOY
Danone PK		 -0.14 0.87% 16.00 28.42 16.39 1.44 2.23 1.85 12.41

Reports Covered

Stock Research & News

View All

Profile

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

USANA Health Sciences Inc

3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120

Key Executives

Name Title Year Born
Mr. Kevin G. Guest Chairman & CEO 1963
Mr. Jim Brown Pres 1969
Mr. G. Douglas Hekking Chief Financial Officer 1970
Mr. Walter Noot Chief Operating Officer 1966
Mr. David Mulham Chief Sales Officer 1960
Dr. Myron W. Wentz Founder & Chairman Emeritus 1941
Dr. John Cuomo Exec. Director of Product Devel. & Technology NA
Dr. Robert A. Sinnott Chief Scientific Officer 1965
Mr. Patrique Richards Exec. Director of Investor Relations & Bus. Devel. NA
Mr. P. Joshua Foukas Chief Legal Officer, Gen. Counsel & Corp. Sec. 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.